

**FOR IMMEDIATE RELEASE**

August 18, 2008

SymBio Pharmaceuticals Limited.

Eisai Co., Ltd.

**SymBio Pharmaceuticals and Eisai Sign License Agreement  
for bendamustine hydrochloride (*SyB L-0501*)**

SymBio Pharmaceuticals Limited. (Headquarters: Tokyo, President and CEO: Fuminori Yoshida, “SymBio”) and Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, “Eisai”) announced today that the companies have concluded the license agreement for the co-development and commercialization of bendamustine hydrochloride in Japan, with exclusive rights retained by SymBio.

Based on this agreement, SymBio shall grant co-development and exclusive commercialization rights to Eisai and, in return, receive upfront and development milestone payments of up to 4 billion yen in total. In addition, the companies plan to move fo

**[Please refer to the contacts below for additional product information and company profile]**

Contacts:

SymBio Pharmaceuticals Limited.

Attn: Mr. Tatsuya Yoneyama

TEL: 81-3-5472-1123

e-mail: